United Arab Emirates

Middle East

Contents

1. Regulatory Overview
2. Regulatory Pathways
3. Available Drugs

Regulatory Overview

United Arab Emirates is regulated by the MOHAP (Ministry of Health and Prevention). The country has 1 documented regulatory pathway for accessing unapproved or unlicensed medicines, covering named patient programs, compassionate use schemes, and special access arrangements.

Regulatory Authority

MOHAP (Ministry of Health and Prevention)

Regulatory Pathways (1)

MOHAP Named Patient Program – UAE 14 days

UAE Ministry of Health and Prevention allows import of unregistered medicines for individual named patients under physician supervision and MOHAP approval.

Application Form: MOHAP NPP Application Form

Legal Basis: Federal Law No. 4 of 1983

Eligibility: Serious or life-threatening condition with no locally registered alternative

Reference: MOHAP Drug Policy

Drugs Available (1)

Drug	Access Route	Status	Lead Time
Nusinersen	Named Patient	Available via NPP	5 days

United Arab Emirates

ISO Code	`AE`
Region	Middle East
Regulatory Authority	MOHAP (Ministry of Health and Prevention)
Pathways	1 documented
Drugs Available	1 drug(s)